ASCO: Targeted therapy combo nearly doubles time without disease progression for patients with advanced colorectal cancer
Cohort 3 of the BREAKWATER trial evaluated encorafenib plus cetuximab with FOLFIRI chemotherapy
Updated results demonstrate improved progression‑free survival, better overall survival and consistent side effects with earlier analyses
Findings build on earlier data showing improved responses and survival outcomes
In February, the FDA approved the BREAKWATER regimen with FOLFIRI as a first‑line option for BRAF V600E-mutant metastatic...
ASCO: UT MD Anderson spotlights emerging precision therapies for rare and difficult-to-treat cancers
ABSTRACTS: 8510, 8008, 6009, 4520
Researchers at The University of Texas MD Anderson Cancer Center will present new findings at the...
Tumor markers in rare appendiceal cancer may predict treatment outcomes
Researchers monitored levels of common blood markers before and after surgery to remove cancer
Study found...
New simulation framework DKOsim advances CRISPR-based gene to gene interaction research
Double-CRISPR Knockout Simulation (DKOsim) is a computer-based “virtual lab” that simulates genomic experiments Studying how genes interact in real cells is difficult, expensive and often produces uncertain results DKOsim allows researchers to test ideas and methods using realistic controlled data while designing more reliable real-world experiments
Researchers at The University...
Low testosterone levels may be associated with increased risk of prostate cancer progression during surveillance
Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer...
Mutation predicts chemotherapy resistance and better responses to immunotherapy in advanced bladder cancer
Researchers studied the KDM6A gene, which is altered in about 26% of advanced bladder cancers
Tumors with KDM6A mutations did not respond well...
Immunotherapy combination does not improve outcomes for patients with advanced anal cancer
Phase II ETCTN trial found ipilimumab plus nivolumab did not improve outcomes over nivolumab alone in...
Targeted therapy plus immunotherapy improved outcomes in advanced metastatic colorectal cancer
Phase III COMMIT trial evaluated better first-line options for patients with dMMR/MSI-H metastatic colorectal cancer
The study...
Study identifies target for disease hyper progression after immunotherapy in kidney cancer
Researchers find that cancer cells mimic myeloid cells to hide from the immune system and promote disease hyper progression after immunotherapy...
HER2-targeted therapy shows promising results in rare bile duct cancers
HER2-positive metastatic biliary tract cancer (BTC) is a rare and aggressive cancer with limited treatment options
Final results from the...
Researchers identify rare mutation that predicts strong immunotherapy response in colorectal cancer
A specific subset of POLE gene mutation, called loss-of-proofreading (LOP) mutations, makes colorectal tumors highly responsive to immunotherapy...
MD Anderson experts spotlight key immunotherapy advances at 2025 SITC Annual Meeting
Major themes include strategies to reprogram the tumor microenvironment and prevent cancer before it starts
New insights from AI-based imaging...
Comprehensive molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and most comprehensive...
New oral therapy shows early signs of safety and effectiveness in patients with advanced, treatment-resistant prostate cancer
Trial shows promising early results for HLD-0915, a first-in-class regulated induced proximity targeting chimera (RIPTAC) treatment
Metastatic...
ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression
First head-to-head study...
ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal...